All In Biotech

Drug Trial Radar · NCT02579044

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 2015

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Boston Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.

Conditions

  • Progeria

Interventions

  • Everolimus and lonafarnibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum-tolerated dose (MTD) of everolimus when administered orally in combination with lonafarnib in subjects with progeriaTime frame: 12 Months
  2. Number and type of dose-limiting toxicities when everolimus and lonafarnib are administered in combination to children with progeriaTime frame: 12 Months
  3. Annual increase in weight gainTime frame: 24 Months
  4. Change in pulse wave velocity (PWV)Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.